- Home
- TOI vs DRUG Comparison
TOI vs DRUG Comparison
Compare TOI & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOI
- DRUG
- Stock Information
- Founded
- TOI 2007
- DRUG 2019
- Country
- TOI United States
- DRUG United States
- Employees
- TOI N/A
- DRUG N/A
- Industry
- TOI Medical/Nursing Services
- DRUG Pharmaceuticals and Biotechnology
- Sector
- TOI Health Care
- DRUG Health Care
- Exchange
- TOI Nasdaq
- DRUG Nasdaq
- Market Cap
- TOI 266.8M
- DRUG 233.2M
- IPO Year
- TOI N/A
- DRUG N/A
- Fundamental
- Price
- TOI $2.39
- DRUG $27.31
- Analyst Decision
- TOI
- DRUG Strong Buy
- Analyst Count
- TOI 0
- DRUG 6
- Target Price
- TOI N/A
- DRUG $83.25
- AVG Volume (30 Days)
- TOI 1.9M
- DRUG 19.9K
- Earning Date
- TOI 08-12-2025
- DRUG 08-13-2025
- Dividend Yield
- TOI N/A
- DRUG N/A
- EPS Growth
- TOI N/A
- DRUG N/A
- EPS
- TOI N/A
- DRUG N/A
- Revenue
- TOI $403,152,000.00
- DRUG N/A
- Revenue This Year
- TOI $23.95
- DRUG N/A
- Revenue Next Year
- TOI N/A
- DRUG N/A
- P/E Ratio
- TOI N/A
- DRUG N/A
- Revenue Growth
- TOI 17.64
- DRUG N/A
- 52 Week Low
- TOI $0.13
- DRUG $0.93
- 52 Week High
- TOI $3.50
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- TOI 38.68
- DRUG 41.95
- Support Level
- TOI $2.28
- DRUG $27.69
- Resistance Level
- TOI $2.87
- DRUG $28.74
- Average True Range (ATR)
- TOI 0.24
- DRUG 1.29
- MACD
- TOI -0.10
- DRUG 0.14
- Stochastic Oscillator
- TOI 1.24
- DRUG 39.29
About TOI The Oncology Institute Inc.
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.